WARSAW, March 12, 2021 - Greenberg Traurig advised mBank S.A. acting as the Manager of the Offering in the offering, through an accelerated bookbuilding process, of newly issued Mabion S.A. shares. The Investors have declared their subscription for all offered 2.43 million shares and the issue price has been set nearly 2.5 times higher than the minimum price calculated in accordance with the authorization expressed in the resolution of the Extraordinary General Meeting of the Company.
The value of the Transaction amounted to over PLN 130 million.
The Greenberg Traurig Warsaw team consisted of Partner Paweł Piotrowski and Associate Jakub Tarłowski.
Mabion is the first Polish biotechnology company active in the development and implementation of the latest generation of biotech drugs based on monoclonal antibody technology. In March 2021 Mabion entered into a framework agreement with Novavax regarding the production of technical batches of antigen for Novavax’ COVID-19 vaccine candidate.
Greenberg Traurig LLP
Greenberg Traurig, LLP is an international, multi-practice law firm with approximately 2200 attorneys serving clients from 40 offices in the United States, Latin America, Europe, Asia, and the Middle East.
Greenberg Traurig Grzesiak sp.k. was named the 2019 and 2018 Most Innovative Law Firm of the Year Award for Poland by International Financial Law Review (IFLR) and the 2017 Law Firm of the Year in Poland by Chambers and Partners. The Warsaw office of Greenberg Traurig, LLP provides legal services to clients in Central Europe and beyond and consists of approximately 100 lawyers. Team members are regularly recognized as leaders in numerous practice areas. Chambers Global, Chambers Europe, IFLR1000 and EMEA Legal 500 consistently rank them among the top tiers the areas of Corporate/M&A, Capital Markets, Real Estate, Private Equity, Tax, Banking and Finance, Project Finance, Energy, Dispute Resolution and TMT.
For additional information, please visit www.gtlaw.com.